Comparative Pharmacology
Head-to-head clinical analysis: FEMCON FE versus PORTIA 21.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FEMCON FE versus PORTIA 21.
FEMCON FE vs PORTIA-21
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive containing norethindrone and ethinyl estradiol. Inhibits ovulation via suppression of gonadotropins (FSH, LH); increases cervical mucus viscosity, impairing sperm penetration; alters endometrial receptivity.
Oral contraceptive: inhibition of ovulation by suppressing gonadotropin release; increases viscosity of cervical mucus, reducing sperm penetration; alters endometrial receptivity.
One tablet (norethindrone 0.5 mg + ethinyl estradiol 35 mcg) orally once daily for 28 days.
One tablet (norgestimate 0.180 mg/ethinyl estradiol 0.035 mg) orally once daily for 21 days, followed by 7 days of placebo.
None Documented
None Documented
The terminal elimination half-life of ethinyl estradiol is 13-18 hours; for norethindrone, it is 7-12 hours. Both allow once-daily dosing for contraceptive efficacy.
Terminal elimination half-life: 24-30 hours; clinical context: steady-state reached after 5-7 days, allows once-daily dosing
Renal excretion accounts for approximately 40-60% of the dose as metabolites; fecal excretion is about 20-30% via bile. Unchanged drug excretion is minimal.
Renal (50-60% unchanged), fecal (30-40% as metabolites), minor biliary
Category C
Category C
Oral Contraceptive
Oral Contraceptive